Shelter Pharma is a 60-year-old Indian maker of natural remedies that began in 1965 when an Ayurvedic practitioner, Mr. N. R. Gandhi, founded a family enterprise in a small Gujarat town to champion herbal healing. Just three years later, it expanded into animal healthcare, creating the dual human-veterinary focus that still defines the company today, and it has since grown from a single location into a listed exporter shipping to more than ten countries. The recurring approach is simple: it formulates Ayurvedic and herbal products for both people and livestock, makes them in one certified factory, and sells them through a doctor-driven field force and a network of stockists - keeping the business nearly debt-free and funding growth from its own cash flows.
Business segments
A single engine with two pistons - human and animal healthcare - powered by one factory, one distribution network, and a shared herbal-medicine heritage.
1. Veterinary healthcare: the larger half of the house
Animal health products - from calcium gels to poultry feed supplements - generate the majority of revenue and reach farmers through tenders, stockists, and export orders.
- Launched almost alongside the company - the veterinary division started in 1968, only three years after founding, so it has been accumulating formulations and customer relationships for nearly six decades.
- A diversified portfolio of 200 products in human healthcare and almost 100 in animal healthcare - the range covers mineral mixtures, multivitamins, anti-diarrheal boluses, calcium supplements, and feed additives, sold under brands like Lactocal Gel, Feedvet powder, and Diarub Bolus.
- Won through government tenders - the company secures institutional orders by bidding on rate contracts, such as a supply deal with Verka Dairies (MILKFED Punjab) won in May 2026 after clearing a technical evaluation.
- Exported to the Middle East and Africa - international customers include Al-Saqr Agro for feed supplements, Genet International for animal feeding preparations, and First Veterinary Medicines Trading in the UAE, with export margins running 20-25% higher than domestic sales.
2. Human healthcare: the brand-builder
Ayurvedic and nutraceutical products for people - led by a lemon-and-barley drink with no direct rival - reach patients through 12,000 doctors and 5,000 pharmacies.
- A 200-formulation cupboard - the human range spans tablets, capsules, syrups, oils, and ointments for conditions like kidney stones, gastric acid, diabetes, and liver dysfunction, with flagship brands including Sherolax laxative, Gashoshel antacid, and Joemega plant-based Omega-3 capsules.
- A unique product with no direct competition - Lemon & Barley Water, a refreshing diuretic, stands alone in the Indian market, giving the company a differentiated entry point with chemists and consumers.
- Nutraceuticals are the growth lane - since 2021, the company has launched a string of supplements including Emune 19, D3 Cure, Beta Glucan, and a zero-sugar pre-workout powder called FitKick Pro that went live on Amazon in March 2026.
- Prescriptions drive the pull - a field force of about 80 people, from national and regional heads down to area sales officers, calls on doctors to generate prescriptions, which are then fulfilled through a chain of super-stockists, district stockists, and retail pharmacies.
Manufacturing and quality: the single-factory backbone
One multi-dosage plant in Himmatnagar, Gujarat, makes every tablet, syrup, powder, and ointment the company sells - and its compliance record is good enough to train government drug inspectors.
- Capacity measured in crores of tablets and lakhs of litres - on a single shift, the plant can produce roughly 35.8 crore tablets, 8.4 lakh litres of liquids, 9.6 lakh kilograms of powder, 2.4 crore capsules, and over a lakh kilograms of ointment each year.
- One of only three companies trusted to train regulators - before COVID, the Gujarat FDCA selected Shelter Pharma as a training site for drug inspectors, a signal of exceptional manufacturing standards.
- A second factory is in the works - the company has already acquired land near Himmatnagar for a new manufacturing facility, preparing for the next phase of capacity expansion.
Distribution and go-to-market: the doctor-plus-stockist engine
Products move through a two-channel system - a field force that generates prescriptions and a layered network of super-stockists and pharmacies that fulfills them.
- One super-stockist per state - the distribution chain flows from state-level super-stockists down to district stockists and then to over 5,000 retail pharmacies, with a separate C&F agent covering Gujarat.
- A sales team of 80, now deepening its bench - the structured hierarchy runs from a national head through regional and state heads to area sales officers, and in early 2026 the company hired a zonal sales manager, a regional manager, three sales officers, and an export executive.
- Credit terms are tightening as the brand strengthens - when the company expanded beyond its original three-state advance-payment territory, it offered 120-day credit to distributors; that has been cut to 90 days, with a target of 60 and eventually 30 days.
- Four ways to market - the strategy splits into branding (brochures, health camps), institutional sales (direct to organisations), OTC retail (distribution support with selective media), and ethical retail (constant doctor engagement with promotional material).
International business: the margin accelerator
Exports to more than ten countries - from Kuwait to Sudan to the UK - deliver margins a fifth to a quarter higher than domestic sales, with many orders paid in full upfront.
- A dedicated export team hunts for partners - the team identifies distributors abroad, showcases samples, and works to register products with foreign health ministries, building a presence country by country.
- Registration wins unlock multi-year access - in 2023, the company secured a five-year registration in Kuwait for its FerroCure nutraceutical capsule, which led to a fixed-cost order worth about Rs. 75 lakhs from its Kuwaiti agent.
- African markets are active and growing - a single order from Sudan for Allvitamins and Joemega capsules was worth roughly Rs. 1 crore, and the company began shipping stocks to Sudan in April 2026 as part of regular African supply.
- Advance payments de-risk the book - export orders can be structured on 100% advance terms, such as on a CNF basis for veterinary supplements, which protects working capital while capturing higher margins.
Group structure and partners
Shelter Pharma is a standalone listed company with no subsidiaries or joint ventures - a family-run operation where the two promoter-directors sit at the top and a handful of international agents open doors abroad.
- Listed on the BSE SME Exchange in August 2023 - the company raised capital through an IPO of 38.16 lakh equity shares at Rs. 42 each, and it reports as a single pharmaceuticals segment under Indian accounting standards.
- No subsidiaries, but the structure allows for them - the company is authorised to deploy funds into subsidiaries or joint ventures in the future, and shareholder approval was obtained in 2024 to increase authorised share capital to Rs. 25 crore.
- A rights issue is on the table - in January 2025, the board approved a plan to raise up to Rs. 50 crore through a rights issue of equity shares, subject to regulatory clearances.
- Key international partners act as local gateways - Berlin International Medicines in Kuwait, Taha Drugs & Chemicals in Sudan, Al-Saqr Agro and Genet International for veterinary feed, and First Veterinary Medicines Trading in the UAE are the named counterparties that place orders and hold product registrations.